Abstract
AbstractDrug metabolism leads to biotransformations of pharmaceutical substances that alter drug efficacy, toxicity, as well as drug interactions. Modeling these processes ex vivo stands to greatly accelerate our capacity to develop safe and efficacious drugs and formulations. Recognizing the liver as the primary site of drug metabolism, here we report a novel whole-tissue ex vivo liver screening platform that enabled modeling of hepatic metabolism and tracking of hepatotoxic drug metabolites. We applied the system for the characterization of acetaminophen (APAP) metabolism and identified interactions that can mitigate the generation of toxic metabolites ex vivo. Combining our experimental platform with state-of-the-art machine learning, we validated two novel functional excipients that can prevent APAP hepatotoxicity in vivo in mice. To assess translational potential, we prototyped a novel solid dosage form with controlled release of both APAP and our functional excipients. Our this platform provides innovative potential access to actionable data on drug metabolism to support the development of new therapeutic approaches.
Publisher
Cold Spring Harbor Laboratory
Reference41 articles.
1. CYP3A genetics in drug metabolism
2. Systems genetics applications in metabolism research;Nat Metab,2019
3. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism;Br J Clin Pharmacol,1990
4. Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation?;J Pharmacol Exp Ther,2001
5. The use of N-acetylcysteine in intensive care;Crit Care Resusc,2002